LifeSci Capital initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $4 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics: Positive KCC2 Platform Progress and Underappreciated Pipeline Optionality Support Reiterated Buy Rating
- Ovid Therapeutics: De-Risked KCC2 Platform and OV329 as Key Drivers of Long-Term Growth Support Buy Rating
- Ovid Therapeutics: Early KCC2 Proof-of-Mechanism and High-Potency OV4071 Pipeline Support Buy Rating and Attractive Long-Term Risk‑Reward
- Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data
- Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV